Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Finn

Showing results (481-490 of 527) with videos related to

Pageof 53
Sort By:
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|October 19, 2021
Circulating Tumor Cell-Based Messenger RNA Scoring System for Prognostication of Hepatocellular Carcinoma: Translating Tissue-Based Messenger RNA Profiling Into a Noninvasive SettingYi-Te Lee, Na Sun, Minhyung Kim, et al.
Cancer Research|October 19, 2007
Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitorJitesh P Jani, Richard S Finn, Mary Campbell, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|June 29, 2024
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatmentAntonino Glaviano, Seth A Wander, Richard D Baird, et al.
Nature Medicine|July 13, 2021
Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysisNicholas A Vitanza, Adam J Johnson, Ashley L Wilson, et al.
Journal of Medical Genetics|July 4, 2009
Mutations in 3 genes (MKS3, CC2D2A and RPGRIP1L) cause COACH syndrome (Joubert syndrome with congenital hepatic fibrosis)D Doherty, M A Parisi, L S Finn, et al.
Lancet (London, England)|December 10, 2016
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialJordi Bruix, Shukui Qin, Philippe Merle, et al.
Lancet (London, England)|January 11, 2025
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 studyMasatoshi Kudo, Zhenggang Ren, Yabing Guo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2024
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract CancerYeong Hak Bang, Choong-Kun Lee, Kyunghye Bang, et al.
The Lancet. Oncology|January 23, 2019
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trialAndrew X Zhu, Yoon-Koo Kang, Chia-Jui Yen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS studyJosep M Llovet, Thomas Decaens, Jean-Luc Raoul, et al.
Pageof 53

Showing results (481-490 of 527) with videos related to

Sort By:
Pageof 53
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|October 19, 2021
Circulating Tumor Cell-Based Messenger RNA Scoring System for Prognostication of Hepatocellular Carcinoma: Translating Tissue-Based Messenger RNA Profiling Into a Noninvasive SettingYi-Te Lee, Na Sun, Minhyung Kim, et al.
Cancer Research|October 19, 2007
Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitorJitesh P Jani, Richard S Finn, Mary Campbell, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|June 29, 2024
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatmentAntonino Glaviano, Seth A Wander, Richard D Baird, et al.
Nature Medicine|July 13, 2021
Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysisNicholas A Vitanza, Adam J Johnson, Ashley L Wilson, et al.
Journal of Medical Genetics|July 4, 2009
Mutations in 3 genes (MKS3, CC2D2A and RPGRIP1L) cause COACH syndrome (Joubert syndrome with congenital hepatic fibrosis)D Doherty, M A Parisi, L S Finn, et al.
Lancet (London, England)|December 10, 2016
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialJordi Bruix, Shukui Qin, Philippe Merle, et al.
Lancet (London, England)|January 11, 2025
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 studyMasatoshi Kudo, Zhenggang Ren, Yabing Guo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2024
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract CancerYeong Hak Bang, Choong-Kun Lee, Kyunghye Bang, et al.
The Lancet. Oncology|January 23, 2019
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trialAndrew X Zhu, Yoon-Koo Kang, Chia-Jui Yen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS studyJosep M Llovet, Thomas Decaens, Jean-Luc Raoul, et al.
Pageof 53